NCT03828292 2025-08-19An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma TreatmentsGlaxoSmithKlinePhase 1 Completed15 enrolled 91 charts